Combination therapy has been pre-evaluated in mouse cancer models where, depending on the model and experimental design, anti-PD-1 or anti-PD-L1 antibody treatment enhanced the antitumor effects of TGFβ inhibition and inhibited tumor metastasis (Mariathasan et al., 2018). The gene discussed is TGFB1; the disease is cancer.